Efficacy and safety of currently approved and lower starting doses of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukemia: a phase IV s... by Muhit Özcan, Ryan D. Cassaday, Ewa Zarzycka, Erik Vandendries, Fan Zhang, Ying Chen, Alejandra Nieto, Fatih Demirkan, Pau Montesinos, Fevzi Altuntas

Get full text

Development and validation of predictive models of early immune effector cell–associated hematotoxicity by Emily C. Liang, Jennifer J. Huang, Andrew J. Portuguese, Valentín Ortiz-Maldonado, Aya Albittar, Natalie Wuliji, Ryan Basom, Yein Jeon, Qian Wu, Aiko Torkelson, Delaney Kirchmeier, Abigail Chutnik, Barbara Pender, Mohamed Sorror, Joshua A. Hill, Noam E. Kopmar, Rahul Banerjee, Andrew J. Cowan, Damian Green, Ajay K. Gopal, Christina Poh, Mazyar Shadman, Alexandre V. Hirayama, Brian G. Till, Erik L. Kimble, Lorenzo Iovino, Aude G. Chapuis, Folashade Otegbeye, Ryan D. Cassaday, Filippo Milano, Cameron J. Turtle, David G. Maloney, Jordan Gauthier

Get full text